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Background: The prevalence of chronic pain and sleep disturbances substantially increases with 
age. Pharmacotherapy remains the primary treatment option for these health issues. However, 
side effects and drug interactions are difﬁcult to control in elderly individuals.
Aims: The objective of this study was to assess the feasibility of conducting a randomized 
sham-controlled trial and to collect preliminary data on the efﬁcacy of transcranial direct 
current stimulation (tDCS) to reduce pain and improve sleep in older adults suffering from 
chronic pain.
Methods: Fourteen elderly individuals (mean age 71o7 years) suffering from chronic pain 
and sleep complaints were randomized to receive either anodal tDCS, applied over the primary 
motor cortex (2 mA, 20 minutes), or sham tDCS, for 5 consecutive days. Pain was measured 
with visual analog scales, pain logbooks and questionnaires, while sleep was assessed with 
actigraphy, sleep diaries and questionnaires.
Results: There were no missing data for pain and sleep measures, except for actigraphy, that 
generated several missing data. Blinding was maintained throughout the study, for both the evalu-
ator and participants. Active but not sham tDCS signiﬁcantly reduced pain (P0.05). No change 
was observed in sleep parameters, in both the active and sham tDCS groups (all P0.18).
Conclusion: The present study provides guidelines for the implementation of future tDCS 
studies in larger populations of elderly individuals. M1 anodal tDCS in this population appears 
to be effective to reduce pain, but not to improve sleep.
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Introduction
Chronic pain and sleep disorders are recognized worldwide as health problems having 
a signiﬁcant impact on quality of life and productivity.1,2 A vicious circle seems to 
govern the interaction between pain and sleep disorders, with chronic pain leading to 
sleep disturbances and poor sleep leading to enhanced pain perception.3–8 It is estimated 
that over 67% of people experiencing chronic pain also complain about their sleep.9,10
The prevalence of chronic pain and sleep disorders increases considerably with 
age.11–14 Pharmacotherapy remains the ﬁrst line of treatment to alleviate sleep dis-
orders and chronic pain symptoms.14–17 Despite the availability of many pharmacological 
approaches, sleep problems and pain often persist.18 In addition, polypharmacy is an 
important challenge in elderly individuals, a population in which drug interactions 
are frequent, and often complex to manage.19
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Past studies have shown that noninvasive brain stimulation 
techniques, such as transcranial direct current stimula-
tion (tDCS), can improve sleep,20 alleviate pain20–24 and 
reduce medication consumption and related side effects.25,26 
However, the majority of these studies were performed on 
young adults suffering from neurogenic pain syndromes, 
and it is still unknown if tDCS could be a valid treat-
ment option for elderly individuals suffering from chronic 
musculoskeletal pain. Investigating the effect of tDCS on 
older populations is crucial given the age-related changes 
observed in brain function and anatomy.27,28 Compared to 
young adults, elderly individuals show reduced gray matter 
perfusion and cerebral oxygen metabolic rate.27 Reduction 
in brain volume has also been documented with aging.29 
Reduction in brain volume increases skull–cortex distance, 
which can presumably affect the effect of tDCS.29,30 The aim 
of the present study was to assess the feasibility of conduct-
ing a randomized, double-blind, sham-controlled trial and to 
collect preliminary data on the efficacy of tDCS to reduce 
pain and improve sleep in older adults suffering from chronic 
musculoskeletal pain.
Materials and methods
Participants
Fourteen elderly individuals were included in the study. Indi-
viduals were regarded as suitable to participate if they fulfilled 
the following criteria: 1) aged 60 years or over, 2) reported 
stable musculoskeletal pain in the previous 3 months or more 
and 3) had a score higher than 7/28 at the Insomnia Sever-
ity Index.31 Participants with tDCS contraindications, such 
as neurological or neuropsychiatric conditions (eg, stroke, 
traumatic brain injury), history of brain surgery or tumor, 
metallic implants, epilepsy or history of substance abuse or 
dependence, were excluded. Participants were asked to keep 
their medication and life habits stable for the duration of the 
study. Participants were also asked not to consume nicotine 
and caffeine at least 6 hours before each visit. The experi-
ment took place at the Research Centre on Aging of CIUSSS 
de l’Estrie-CHUS (Sherbrooke, QC, Canada). Subjects 
were all French-speaking community-dwelling individuals. 
The study was approved by the Research Ethics Committee 
of CIUSSS de l’Estrie-CHUS, and written informed consent 
was obtained from all participants. All procedures performed 
were in accordance with the ethical standards of the local 
institutional research committee and with the Declaration 
of Helsinki of 1964 and its later amendments or comparable 
ethical standards.
experimental design
A randomized, parallel, double-blind, sham-controlled design 
was used. The study lasted 19 days and was divided into 
3 phases: 1) a 7-day baseline evaluation; 2) a 1-week double-
blind treatment period, which consisted of 5 consecutive 
daily treatment sessions of sham or active tDCS and 3) a 
7-day follow-up period (Figure 1). Throughout the 19 days 
of the study, daily measures of sleep and pain were recorded. 
Randomization to sham or active tDCS was performed using 
a random numbers table with a ratio of 1:1, based on order of 
entry of the participants in the study. The randomized table 
was designed to assign a total of 16 subjects to the study 
(8 in each group).
Pain measurements
Pain intensity was evaluated with a visual analog scale 
(VAS) and a pain logbook. The VAS is a self-assessment 
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Figure 1 The study lasted 19 days and was divided into 3 phases: T1 (baseline), T2 (tDCs treatments) and T3 (follow-up). Pain and sleep questionnaires were completed at 
the beginning of the study (day 1), after the 5 tDCs sessions (day 12) and after the 7 days of follow-up (day 19). Actigraphic measures were taken from day 1 to day 19. Pain 
and sleep logbooks were completed each day, at home, by the participants, from day 1 to day 19.
Abbreviation: tDCs, transcranial direct current stimulation.
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scale of 10 cm that ranges from “no pain” (0 cm) to “the 
worst imaginable pain” (10 cm). This scale is widely used 
to evaluate pain outcome in studies, and its validity is 
well established.32,33 Participants had to rate pain intensity 
in the laboratory with a VAS once on day 1 and day 19, 
and before and after each tDCS session (day 8 to day 12). 
In addition to the VAS pain score, participants were asked 
to rate their daily pain in a pain assessment logbook contain-
ing 3 numerical rating scales (NRSs) ranging from 0 to 10 
(0= no pain; 10= maximal pain). These 3 NRSs were used to 
evaluate the pain felt by the participant 1) at its least during 
the last 24 hours (minimal pain), 2) at its worst during the 
last 24 hours (maximal pain) and 3) on average in the last 
24 hours (average pain). The pain assessment logbook was 
filled out by the participant at the end of each day through-
out the duration of the study. The NRSs have been shown 
to be reliable and valid to measure pain intensity in elderly 
patients with persistent pain.34 Pain assessments with the 
VAS were used in the laboratory to measure current pain, 
while the pain logbook was used to reflect the pain for each 
day. Although the pain intensity measurement is essential, 
it captures only part of the pain experience in older patients 
and should be supplemented by other pain measures.33,34 
Consequently, pain questionnaires such as the McGill Pain 
Questionnaire (MPQ) and the Short Form of the Brief Pain 
Inventory (SF-BPI) were used to assess qualitative aspects of 
pain and physical functioning, respectively. These question-
naires were completed 3 times during the study (ie, on day 
1, 12 and 19; Figure 1). The validity and reliability of both 
questionnaires have been previously documented.35–38
sleep measurements
Sleep efficiency, which is the ratio of total time spent in 
bed to total time actually spent sleeping, was evaluated 
with actigraphy (Model Actiwatch; Philips – Respironics, 
Murrysville, PA, USA). Actigraphic records were also used 
to quantify nocturnal awakenings and estimate sleep-onset 
latency. Participants were asked to wear the actigraph device 
on their nondominant wrist throughout the duration of the 
study. Actigraphy has been shown to be a reliable method 
of recording activity during sleep.39,40 Actigraphic record-
ings were supplemented with the data collected in the sleep 
diary; during their participation in the study, from day 1 to 
day 19, participants were asked to fill out a sleep diary col-
lecting information on the quality and quantity of sleep that 
they perceived. In addition to the actigraph and the sleep 
diary, the Pittsburgh Sleep Quality Index (PSQI) was used 
to assess the participant’s sleep quality. The PSQI showed a 
strong validity and reliability in both clinical and nonclini-
cal samples.41 Finally, 1 question of the SF-BPI, based on a 
0–10 NRS, and labeled “Circle the one number that describes 
how, during the past 24 hours, pain has interfered with your 
sleep”, was used to assess pain interference with sleep (0= 
does not interfere; 10= completely interferes).
tDCs protocol
Participants were seated comfortably in an armchair during 
the 5 tDCS treatment sessions. The stimulations for a given 
subject were always done by the same investigator who was 
different from the evaluator. The investigator was responsible 
for the assignment of participants to the active or sham tDCS 
group, while the evaluator and the participants were blinded. 
The stimulations were always given in the afternoon or in the 
evening to get as close as possible to the actual time period 
of the night of sleep. Direct current was transferred to the 
subject by a saline-soaked pair of surface sponge electrodes 
(5×7 cm) and delivered by a constant current stimulator, 
battery-driven, 1×1 tDCS device (Model 1300-A; Soterix 
Medical Inc, New York, NY, USA). Participants received 
either anodal stimulation of the primary motor cortex (M1) 
or sham stimulation of M1. The anodal electrode was placed 
over M1, contralateral to the most painful site (C3 or C4 per 
the electroencephalogram 10/20 system), and the cathodal 
electrode was placed on the supraorbital area contralateral 
to the anode. During active tDCS, a constant anodal current 
of 2 mA was delivered for 20 minutes. This anodal tDCS 
procedure is known to increase cortical excitability and to 
reduce pain.20,21,23,42,43 This procedure has also been shown 
to improve sleep in patients suffering from fibromyalgia.20 
For the sham stimulation, the electrodes were placed in the 
same montage as the active tDCS; however, current was 
applied only for the initial and final 30 seconds. Therefore, the 
patients felt the ramp-up and ramp-down itching sensation of 
the current, but received no current for the rest of the stimula-
tion period. This placebo procedure has been validated and is 
now successfully used in most studies using tDCS.44–46 The 
tDCS device was set by the manufacturer to automatically 
provide this type of sham stimulation.
Data analysis
The feasibility of the study was evaluated with regard to the 
challenges incurred by the data collection and the number of 
missing data for every pain and sleep measurement tool. Also 
documented were the number of participants who completed 
the study, the ability to maintain blinding for the evaluator 
and participants, as well as randomization issues.
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Preliminary analysis on the effectiveness of the tDCS 
intervention was also conducted. To facilitate interpretation 
and to reduce the number of statistical comparisons, pain 
intensity ratings (pain logbook) and actigraphy measure-
ments (sleep efficiency, sleep-onset latency and number of 
nocturnal awakenings) were averaged into 3 scores, reflecting 
the 3 phases of the study (ie, before, during and after tDCS 
treatment). As shown in Figure 1, T1 represents the 7 days of 
baseline, T2 corresponds to the 5 days of tDCS treatments 
and T3 represents the 7 days of follow-up. The mean values 
were used for all analyses. Percentages of change were also 
calculated to directly compare the efficacy of active tDCS 
and sham tDCS on pain and sleep, based on the following 
formula: percentage of change = [(score during or after 
treatment (T2 or T3) − score before treatment (T1))/score 
before treatment (T1)] ×100.
The study was designed to detect a clinically important 
difference of 2 points on the 0–10 pain intensity scale.47 
To detect this difference with 80% power and a 5% sig-
nificance level, we determined that 16 individuals had to be 
enrolled in the study (estimated standard deviation of 1.3, 
based on previous tDCS studies23,24). Because of the low 
number of subjects, and since visual inspection of the 
histograms did not allow us to assume that the data were 
normally distributed, nonparametric tests were used for all 
the statistical analyses. Specifically, Mann–Whitney tests 
(continuous variables) and Fisher’s exact tests (categorical 
variables) were used to compare the 2 groups (between-
subject analyses). This allowed us to evaluate if the outcome 
measures were different between the active and sham tDCS 
groups. Friedman tests and Wilcoxon signed-rank tests were 
also used to compare if the intervention affected the outcome 
measures in each group (intragroup analyses). All tests were 
performed using SPSS (version 17.0 for Windows; SPSS Inc., 
Chicago, IL, USA), and differences were considered to be 
significant if P,0.05 was obtained. Bonferroni corrections 
were applied to prevent type I errors.
Results
Participants’ characteristics
Sixteen elderly individuals aged between 62 and 84 years 
(mean age 71±7 years; 3 men) were included in the study. 
Two participants from the active tDCS group dropped out of 
the study, 1 because of a family event (death of a loved one) 
and 1 because of a personal matter (withdrawal of driver’s 
license). The demographic and general clinical characteristics 
of the remaining 14 participants are summarized in Table 1. 
Participants had no change in medication during the last 
3 months. Exploratory analyses and visual inspection of 
the data revealed that the medication had no effect on the 
response to tDCS, for pain as well as for sleep.
Pain outcomes
There were no missing data for all pain outcomes. The 
participants correctly filled all pain measures and question-
naires. However, the VAS often needed explanations before 
the participants could fully grasp the concept evaluated. After 
the first laboratory session, the concept of pain measures was 
well understood by the participants, and all the daily pain 
logbooks were completed correctly.
The VAS pain scores obtained on day 1 and day 19, and 
before and after each tDCS session (day 8 to day 12) in the 
laboratory are presented in Figure 2. As it can be seen from 
this figure, no significant change was observed immediately 
after each tDCS session, for both the active and sham tDCS 
group. The absence of short-term effect was confirmed by the 
Friedman and Wilcoxon signed-rank tests, which revealed no 
significant intragroup differences for both treatment groups 
(all P$0.17). Mann–Whitney tests also showed that there 
were no between-group differences for all time measures 
(all P$0.11) suggesting, again, that tDCS has no short-term 
effect on pain.
Daily average pain ratings, obtained via the pain logbook 
for the 3 phases of the study, are presented in Figure 3 and in 
Table 2. As can be seen from this figure, daily average pain 
ratings decreased among the active tDCS group and slightly 
increased among the sham tDCS group. This pattern of 
results was confirmed by the Friedman tests, which revealed 
a change in pain for both tDCS conditions (both P#0.03). 
For the active tDCS group, post hoc Wilcoxon signed-rank 
tests revealed that there was a significant reduction in daily 
average pain during (T2; P=0.04) tDCS treatments, when 
compared to baseline (T1). A significant trend was also 
observed for T3 (P=0.06). In contrast, post hoc Wilcoxon 
signed-rank tests showed that sham tDCS slightly increased 
pain at T3 when compared to T1 (+0.34±0.29; P=0.04).
To better evaluate the effect of active and sham tDCS, 
percentages of hypoalgesia were calculated (Figure 4). 
On one hand, active tDCS produced a reduction in pain of 
28% at T2 and of 49% at T3. Both these percentages of pain 
reduction are clinically significant.48 On the other hand, sham 
tDCS reduced pain by 7% at T2 and increased pain by 19% 
at T3. These percentages of change observed among the sham 
tDCS group are not clinically significant. Mann–Whitney 
tests comparing the active tDCS group and the sham tDCS 
group revealed a significant difference between the groups 
at T3 (P=0.008), but not at T2 (P=0.31).
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Table 1 Clinical and demographic characteristics of the participants
Variable All participants Active tDCS Sham tDCS P-value*
number (n) 14 6 8
gender (F/M)‡ 11/3 5/1 6/2 1.00
hand dominance (right/left)‡ 14/0 6/0 8/0 1.00
Age (years)
Mean ± standard deviation† 71±7 72±6 71±8 0.56
range 62–84 67–83 62–84
Baseline pain score (T1)† (average daily pain – pain logbook) 4.3±2.9 6.3±3.1 2.7±1.4 0.10
etiology of pain
Osteoarthritis 4 3 1
sprained shoulder 1 1
Chronic low back pain 4 2 2
Cervical injury 1 1
shoulder tendonitis 1 1
Polymyalgia rheumatica 1 1
sciatica 1 1
Unspecific leg pain 1 1
side of the most problematic pain (right/left)‡ 8/6 4/2 4/4 0.41
Duration of chronic pain
less than 2 years 2 1 1
Between 2 and 10 years 3 1 2
More than 10 years 9 4 5
Mean ± standard deviation† 20±18 26±24 15±11 0.48
Baseline IsI score† 14.9±5.2 15.0±6.4 14.9±4.7 0.39
Baseline sleep efficacy (T1)† 85.9±7.0 86.4±7.5 85.5±8.1 0.83
Baseline quantity of nocturnal awakenings (T1)† 53.9±28.4 50.2±32.3 56.6±27.1 0.90
Duration of sleep complaints
less than 2 years 2 1 1
Between 2 and 10 years 5 1 4
More than 10 years 7 4 3
Mean ± standard deviation† 21±22 28±25 16±19 0.44
Present medication
Pregabalin 2 1 1
Benzodiazepine 4 3 1
nsAID 3 1 2
Morphine 1 1
snrI 2 2
Tricyclic antidepressant 2 2
levothyroxine 4 2 2
β-Blocker 3 2 1
AsA 2 1 1
PPI 3 2 1
statin 5 2 3
ArB 2 1 1
Thiazide diuretic 1 1
ACe inhibitor 1 1
Triptan 1 1
no medication 2 1 1
Other health problem
Myalgic encephalomyelitis 1 1
Myocardial ischemia 1 1
hypercholesterolemia 5 2 3
Angina pectoris 1 1
hypertension 4 2 2
hypothyroidism 4 2 2
no other health problem 6 2 4
Notes: some participants had more than 1 health problem and medication; consequently, the total number of health problems and medications does not correspond to the 
total number of participants in each group. *P-value of the comparison between active tDCs group and sham tDCs group. ‡Fisher’s exact test. †Mann–Whitney test. Data 
presented as mean ± standard deviation or n.
Abbreviations: tDCS, transcranial direct current stimulation; F, female; M, male; ISI, Insomnia Severity Index; NSAID, nonsteroidal anti-inflammatory drug; SNRI, serotonin–
norepinephrine reuptake inhibitor; AsA, acetylsalicylic acid; PPI, proton pump inhibitor; ArB, angiotensin II receptor blocker; ACe, angiotensin-converting enzyme; T1, 7-day 
baseline.
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Table 3 shows the results of pain questionnaires for each 
time point. Active tDCS generated a significant change in 
MPQ scores. Post hoc Wilcoxon signed-rank tests revealed 
that tDCS reduced MPQ scores at T2 and T3, when compared 
to baseline (T1) (all P#0.04), suggesting that active tDCS 
can affect the qualitative aspects of pain. No changes over 
time were noted for physical functioning, as measured by the 
SF-BPI for both active and sham tDCS groups (P$0.07). 
There were no between-group differences, according to both 
questionnaires, for all time measures (all P$0.07).
sleep outcomes
The actigraphic measures generated several missing data, and 
the analyses of sleep efficiency and sleep-onset latency were 
done only for 4 participants (2 participants by group), which 
dangerously reduced the power of the statistical analysis. 
Still, visual inspection of the diagrams showed no trend 
toward a difference between the 2 participants who received 
active tDCS and the 2 participants who received sham tDCS. 
Intragroup inspection revealed that active tDCS seems to 
decrease sleep efficiency at T2 and T3 (approximately −7% 
and −1%, respectively) (all P$0.20), to increase sleep-onset 
latency at T2 (+12 minutes) and to decrease sleep latency at 
T3 (−34 minutes) (all P$0.22).
There were no missing data for the number of nocturnal 
awakenings evaluated with actigraphy and for the sleep diary 
measures and sleep questionnaires (PSQI and SF-BPI). There 
was no change in nocturnal awakenings at T2 and T3 when 
compared to T1 in the active tDCS group (approximately +4 
and +5 awakenings, respectively), nor in the sham tDCS group 
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Figure 2 Pain intensity scores measured with VAs for active and sham tDCs groups. Pain scores were obtained once on day 1 and day 19, and before and after each tDCs 
session (day 8 to day 12). each point represents group mean ± standard error of mean.
Abbreviations: VAs, visual analog scale; tDCs, transcranial direct current stimulation.
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Figure 3 The average daily pain for sham and active treatment groups gathered 
using the pain logbook. T1 represents the 7 days of baseline, T2 corresponds to 
the 5 days of tDCs treatments and T3 represents the 7 days of follow-up. each 
point represents a group mean ± standard error of mean. There was a significant 
difference between T1 and T2 in the active tDCs group and between T1 and T3 in 
sham tDCS group. *Statistically significant (P,0.05).
Abbreviations: tDCs, transcranial direct current stimulation; T1, baseline; T2, 
tDCs treatments; T3, follow-up.
Table 2 etiology of pain and daily average pain ratings of the 
3 phases of the study
Participant Group Etiology of pain Pain score
T1 T2 T3
1 Active tDCs Osteoarthritis 8.3 6.3 4.9
2 Cervical injury 10.0 8.9 10
3 Osteoarthritis 8.6 2.1 1.2
4 Osteoarthritis 4.5 3.9 2.3
5 Chronic low back pain 3.4 3.0 1.2
6 Chronic low back pain 2.7 2.1 1.5
7 sham tDCs sprained shoulder 4.2 3.7 4.2
8 shoulder tendonitis 1.3 1.3 1.6
9 Osteoarthritis 3.9 2.6 3.9
10 Chronic low back pain 1.0 0.8 1.4
11 Polymyalgia rheumatica 4.0 4.0 4.2
12 sciatica 2.4 2.6 3.5
13 Unspecific leg pain 1.1 1.4 1.5
14 Chronic low back pain 4.0 3.2 4.3
Abbreviations: tDCs, transcranial direct current stimulation; T1, baseline; T2, 
tDCs treatments; T3, follow-up.
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(approximately −8 awakenings for both time measures) (all 
P$0.57). Mann–Whitney tests showed that there were no 
between-group differences in nocturnal awakenings for all 
time measures (all P$0.69). The data collected with the sleep 
diaries revealed that patients observed no difference in their 
sleep during or after the active and sham tDCS treatments. 
Table 3 shows that there was no change in sleep questionnaires 
scores during and after tDCS when compared to baseline, for 
both the active and sham tDCS group (all P$0.12). Mann–
Whitney tests also showed that there were no between-group 
differences for all time measures (all P$0.22).
Discussion
The first objective of the present study was to provide infor-
mation regarding the feasibility of conducting a randomized, 
double-blind, sham-controlled trial considering the efficacy 
of tDCS to reduce pain and improve sleep in older adults suf-
fering from chronic musculoskeletal pain. Although no major 
obstacles prevented the completion of the study, some impor-
tant recommendations can be made. First, using a stratified ran-
domization strategy for key factors (eg, baseline pain levels) 
appears to be of primary importance.49,50 This is particularly 
true for small-sample-size studies, as conventional simple 
randomization methods can generate imbalances in base-
line characteristics among groups.49,50 In the present study, 
despite randomization, the group that received active tDCS 
treatments had higher levels of baseline pain, compared to 
the group that received sham tDCS. Even if this difference 
was not statistically significant, baseline differences in core 
outcome measures are always problematic. In the present 
case, it remains possible that the pattern of results observed 
(ie, greater effect of active tDCS than sham tDCS) is partly 
attributable to the fact that it is easier to provide pain relief 
when initial pain is high.48 Despite the fact that increasing the 
number of participants could help attenuate baseline group 
differences, we suggest that future studies should random-
ize patients according to their initial pain. Second, although 
pain measures and questionnaires were correctly understood 
by the participants, these measures often required several 
explanations before participants could fully grasp the concept 
evaluated. Even though the pain scales and questionnaires 
used in this study (eg, VAS, MPQ, Brief Pain Inventory) are 
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Figure 4 Percentages of hypoalgesia calculated with the average pain on the day 
measured using the pain logbook. The first 2 columns represent hypoalgesia during 
the week of tDCs treatments (comparing T2 to T1), and the next 2 columns represent 
hypoalgesia during the 7 days of follow-up (comparing T3 to T1). each column 
represents mean ± standard error of mean. *Statistically significant (P,0.05).
Abbreviations: tDCs, transcranial direct current stimulation; T1, baseline; T2, 
tDCs treatments; T3, follow-up.
Table 3 Pain and sleep questionnaires
Questionnaire tDCS group Scores P-value†
Baseline (day 1) Post-tDCS (day 12) Follow-up (day 19)
MPQ Active 32.2±13.7 16.2±8.1 21.5±17.6 0.02*
sham 23.8±16.3 24.4±14.1 22.8±7.8 0.80
P-value‡ 0.25 0.22 0.80
sF-BPI Active 29.0±11.0 12.2±10.2 17.6±17.3 0.07
sham 17.1±10.3 11.0±8.7 11.8±8.1 0.17
P-value‡ 0.07 0.80 0.56
sF-BPI (pain interference with sleep) Active 6.5±1.9 3.3±3.4 5.2±5.0 0.12
sham 4.8±2.5 3.0±2.4 3.8±2.8 0.24
P-value‡ 0.22 0.90 0.77
PsQI Active 12.0±2.8 10.2±3.9 10.3±6.6 0.57
sham 9.8±3.9 9.9±2.4 8.0±2.4 0.12
P-value‡ 0.24 0.84 0.40
Notes: Data are presented as mean value ± standard deviation and 95% confidence interval. †Friedman tests were performed to detect intragroup differences. *statistically 
significant. ‡Mann–Whitney tests were performed to detect between-group differences.
Abbreviations: tDCs, transcranial direct current stimulation; MPQ, Mcgill Pain Questionnaire; sF-BPI, short Form of the Brief Pain Inventory; PsQI, Pittsburgh sleep 
Quality Index.
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designed to be self-administered, these observations indicate 
that the presence of a member of the research team is essen-
tial to ensure valid pain measures in studies conducted in 
elderly individuals. Of importance, the results show that the 
use of NRS (included in the pain logbooks) is appropriate 
to evaluate changes in the daily pain of elderly chronic pain 
patients. NRS appears to be a simpler tool to understand than 
VAS, an observation that is coherent with that of Dworkin 
et al33 and Herr.51
Blinding of the participants and of the evaluators is 
always a major concern of randomized controlled studies. 
In a commendable study published recently by O’Connell 
et al, the authors suggest that the use of a sham tDCS treat-
ment, applied at an intensity of 2 mA, is hardly attainable.52 
Indeed, based on the sensation of the stimulation, 65% of 
the participants correctly judged the stimulation condition 
(active or sham), while evaluators noticed skin changes 
(redness) under the reference electrode more often following 
active tDCS than sham tDCS.52 In our case, none of the 
participants, nor the evaluator, were able to distinguish 
between the 2 types of stimulation (sham or active tDCS).52 
Contrary to O’Connell et al, the participants included in 
this study were elderly individuals. Perhaps the age-related 
changes observed in tegumentary and sensory functions 
(eg, decreased sensation and skin thickness) could explain 
these discrepancies.53–55 Indeed, all the participants (includ-
ing those who received sham tDCS, and therefore, only 
60 seconds in total of real stimulation) presented some red-
ness under the reference electrode.
Participants wore the actigraph without problems during 
the 19 days of the study. Although some studies consider that 
actigraphy is a valid method to assess sleep, it is important 
to mention that in our study, the use of actigraphy led to 
many missing data.56,57 The analyses revealed that many 
participants tended to be immobile in bed, even when awake, 
thus leading to several incorrect or missing data concerning 
sleep-onset latency (a measure that is also used to calculate 
sleep efficiency). Consequently, measuring sleep efficiency 
with actigraphy is probably not the best strategy in older 
populations. Although costlier and more time consuming, 
future studies should consider using polysomnography 
instead of actigraphy.58 However, the absence of changes 
noted in the subjective measures of sleep (sleep diaries and 
questionnaires) sheds some doubt on the potential utility of 
tDCS to decrease sleep problems in elderly individuals and 
somewhat diminishes the interest for the implementation 
of a polysomnography study in this population. As for pain 
questionnaires, many participants needed help to complete 
the sleep questionnaires, highlighting once again the key role 
of the research team.
effect of tDCs on pain intensity
Among the active tDCS group, there was a significant 
reduction in daily average pain during tDCS treatments 
(T2), when compared to baseline (T1). Of importance, the 
reduction in pain observed at T2 was clinically significant 
for patients suffering from chronic musculoskeletal pain.48 
Moreover, despite the fact that the reduction of the average 
daily pain in the follow-up (T3) was not statistically signifi-
cant when compared with T1, it is important to note that the 
pain reduction provided by the active tDCS between T1 and 
T3 is almost 3 points on the NRS. Thus, this reduction in the 
average daily pain is clinically significant and associated with 
the concept of a “much better” improvement in pain.48,59 The 
large variability in tDCS-induced pain reductions observed at 
T3 in the active tDCS group can probably explain why this 
important difference did not reach statistical significance. 
Concerning the sham tDCS group, there was an increase in 
the average daily pain at T3 when compared to T1. Although 
these differences are statistically significant, they are not 
clinically significant.
Many of the previous studies considering the analgesic 
efficacy of tDCS were conducted with young or age-
heterogeneous populations, and on patients suffering from 
neuropathic pain. In one of the first studies published on the 
effect of tDCS on pain, Fregni et al21 evaluated the analgesic 
efficacy of tDCS in a group of 17 subjects with spinal cord 
injuries (mean age: 35.7±13.3 years). The authors reported 
that tDCS, applied for 20 minutes at 2 mA for 5 consecutive 
days, reduced pain in this patient population, suggesting that 
this stimulation protocol is effective in adults suffering from 
neuropathic pain, a conclusion that was substantiated by many 
other studies.23,42 These results contrast with those of Wrigley 
et al who observed no effect of tDCS on the pain in patients 
suffering from neuropathic pain conditions.60 Very few stud-
ies looked into the analgesic efficacy of tDCS on chronic 
musculoskeletal pain. Antal et al have assessed the analgesic 
quality of tDCS in patients suffering from chronic musculo-
skeletal or neuropathic pain (age range: 41–70 years).22 They 
reported that anodal tDCS produced a 30% reduction in pain 
after the fifth and last session of stimulation. Interestingly, 
this decrease in pain after 5 anodal sessions of tDCS was like 
that of the present study (average reduction of 28% when 
comparing T2 to T1). For their part, Schabrun et al observed 
a decrease in pain for almost 60% of patients with chronic 
low back pain (CLBP) (mean age: 30±2 years).61 However, 
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the age difference between the population in Schabrun et 
al’s study and the current study makes any comparison 
somewhat hazardous. A recent study published by Concerto 
et al assessed the analgesic efficiency of tDCS on 10 elderly 
patients with plantar fasciitis (mean age: 68.8±3.3 years).62 
This study showed a decrease in pain that was relatively 
identical to that of the current study (36.9% vs 28% during 
the 5 days of treatment and 42.4% vs 49% on the week after 
the treatment). To our knowledge, Concerto et al’s pilot study 
is the only other study that looked at the analgesic effect of 
tDCS in elderly individuals. Although interesting, it should 
be noted that the results of Concerto et al were obtained using 
an open-label design, with no placebo condition. This can 
be problematic given the important placebo effect noted in 
studies looking into the analgesic effect of brain stimulation 
techniques.63
The long-term effect of tDCS has been measured in 
several studies. In one of their studies, Fregni et al reported 
that the pain improvement induced by 5 sessions of tDCS in 
women with fibromyalgia was still apparent 3 weeks after 
the stimulation sessions.64 Similarly, Valle et al demonstrated 
that 10 sessions of tDCS could reduce pain in women suf-
fering from fibromyalgia (mean age: 54.8±9.6 years) for a 
period of 60 days, whereas Auvichayapat et al reported that 
20 sessions of tDCS produced a decrease in pain for a period 
of 12 weeks in patients suffering from migraines (mean age: 
28.6±6.8 years).65,66 Increasing the number of tDCS sessions 
could produce cumulative and more long-lasting effects.67 
In contrast, O’Connell et al showed that tDCS did not produce 
a significant effect on the pain in patients with CLBP (mean 
age: 45±10 years), regardless of the number of sessions.68
effect of tDCs on sleep
To our knowledge, only 1 study specifically focused on the 
effect of tDCS on sleep structure in patients suffering from 
chronic pain. In this study, Roizenblatt et al aimed to deter-
mine if the application of tDCS in women suffering from 
fibromyalgia could decrease pain, as well as improve sleep 
quality.20 Using polysomnography, the authors observed 
that 5 sessions of anodal tDCS stimulation applied over the 
primary motor cortex improved sleep parameters and archi-
tecture in patients suffering from fibromyalgia. In the present 
study, no benefits were observed on sleep variables following 
tDCS applications. It is important to note that, although 
the populations examined in this study and in the study of 
Roizenblatt et al both suffered from chronic pain, the type of 
pain, as well as the sex and the age of participants, was quite 
different.20 Past research has shown that sleep mechanisms 
are different in elderly individuals when compared to young 
adults (eg, sleep–wake cycle, more frequent and longer 
periods of awakening, wake-up time in the morning, sleep 
satisfaction, percentage of slow-wave sleep and rapid eye 
movement sleep).11,14,69–72 These differences may explain why 
tDCS did not have an impact on the elderly, whereas it was 
effective in younger adults. Furthermore, contrary to fibro-
myalgia (in which sleep disorder is generally recognized as 
a primary symptom73), the sleep disorders experienced by the 
participants of this study were secondary to pain problems. 
Perhaps, a longer follow-up would have allowed us to detect 
sleep changes in our participants.
Although they did not assess the effect of tDCS on sleep 
structure, other authors have focused on the effect that 
tDCS has on sleep. In one of these studies, Borckardt et al 
measured the analgesic effect of tDCS in patients who had 
undergone endoscopic retrograde cholangiopancreatography 
(ERCP).26 They found that the patients who received real 
tDCS (10 women, mean age: 37.8±10.8 years) reported less 
pain interference with sleep (according to 1 question of the 
BPI) than those who received sham tDCS. In the present 
study, no change was noted following tDCS for the same 
question from the BPI. It is however important to note that 
the results of Borckardt et al’s study are the result of the 
analyses of only 24 hours post-ERCP.
Conclusion
The present study provides preliminary evidence on the 
efficacy of tDCS to reduce pain and improve sleep in older 
adults, as well as guidelines for the implementation of future 
studies. tDCS appears to be a promising therapeutic avenue 
for older individuals suffering from chronic musculoskeletal 
pain. Future studies evaluating the effect of tDCS on sleep 
should consider the shortcomings of actigraphic measures 
and should strongly consider using polysomnography.
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